Sha HH - Search Results

1

MiR-138: A promising therapeutic target for cancer.

Sha HH, Wang DD, Chen D, Liu SW, Wang Z, Yan DL, Dong SC, Feng JF. Sha HH, et al. Tumour Biol. 2017 Apr;39(4):1010428317697575. doi: 10.1177/1010428317697575. Tumour Biol. 2017. PMID: 28378633 Free article. Review.

2

miR-222 confers the resistance of breast cancer cells to Adriamycin through suppression of p27(kip1) expression.

Wang DD, Li J, Sha HH, Chen X, Yang SJ, Shen HY, Zhong SL, Zhao JH, Tang JH. Wang DD, et al. Among authors: sha hh. Gene. 2016 Sep 15;590(1):44-50. doi: 10.1016/j.gene.2016.06.013. Epub 2016 Jun 6. Gene. 2016. PMID: 27282281

3

miR-197: A novel biomarker for cancers.

Wang DD, Chen X, Yu DD, Yang SJ, Shen HY, Sha HH, Zhong SL, Zhao JH, Tang JH. Wang DD, et al. Among authors: sha hh. Gene. 2016 Oct 15;591(2):313-9. doi: 10.1016/j.gene.2016.06.035. Epub 2016 Jun 17. Gene. 2016. PMID: 27320730 Review.

4

Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.

Sha HH, Wang DD, Yan DL, Hu Y, Yang SJ, Liu SW, Feng JF. Sha HH, et al. Biosci Rep. 2017 Jan 27;37(1):BSR20160332. doi: 10.1042/BSR20160332. Print 2017 Feb 28. Biosci Rep. 2017. PMID: 28053197 Free PMC article. Review.

5

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.

Hu Y, Zang J, Cao H, Wu Y, Yan D, Qin X, Zhou L, Fan F, Ni J, Xu X, Sha H, Liu S, Yu S, Wang Z, Ma R, Wu J, Feng J. Hu Y, et al. Oncotarget. 2017 Feb 28;8(9):15802-15814. doi: 10.18632/oncotarget.15007. Oncotarget. 2017. PMID: 28178657 Free PMC article.

6

Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.

Hu Y, Qin X, Yan D, Cao H, Zhou L, Fan F, Zang J, Ni J, Xu X, Sha H, Liu S, Yu S, Wu J, Ma R, Feng J. Hu Y, et al. Tumour Biol. 2017 Mar;39(3):1010428317691659. doi: 10.1177/1010428317691659. Tumour Biol. 2017. PMID: 28345454 Free article.

7

MiR-29a: a potential therapeutic target and promising biomarker in tumors.

Wang JY, Zhang Q, Wang DD, Yan W, Sha HH, Zhao JH, Yang SJ, Zhang HD, Hou JC, Xu HZ, He YJ, Hu JH, Zhong SL, Tang JH. Wang JY, et al. Among authors: sha hh. Biosci Rep. 2018 Feb 8;38(1):BSR20171265. doi: 10.1042/BSR20171265. Print 2018 Feb 28. Biosci Rep. 2018. PMID: 29217524 Free PMC article. Review.

8

6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: a promising new anticancer compound.

Sha HH, Wang Z, Dong SC, Hu TM, Liu SW, Zhang JY, Wu Y, Ma R, Wu JZ, Chen D, Feng JF. Sha HH, et al. Biosci Rep. 2018 Feb 13;38(1):BSR20171440. doi: 10.1042/BSR20171440. Print 2018 Feb 28. Biosci Rep. 2018. PMID: 29358310 Free PMC article. Review.

9

Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer.

Chen D, Sha H, Hu T, Dong S, Zhang J, Liu S, Cao H, Ma R, Wu Y, Jing C, Wang Z, Wu J, Feng J. Chen D, et al. Cell Death Dis. 2018 Mar 6;9(3):366. doi: 10.1038/s41419-018-0404-5. Cell Death Dis. 2018. PMID: 29511158 Free PMC article.

10

LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt-NF-κB activation.

Liu S, Cao H, Chen D, Yu S, Sha H, Wu J, Ma R, Wang Z, Jing C, Zhang J, Feng J. Liu S, et al. Oncol Lett. 2018 May;15(5):7168-7174. doi: 10.3892/ol.2018.8182. Epub 2018 Mar 6. Oncol Lett. 2018. PMID: 29731879 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page